Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Intraocular Lymphoma 1Hodgkin Disease 1Gastrointestinal Stromal Tumors 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

Doxorubicin 3Dexrazoxane 3Cyclophosphamide 3Razoxane 2Neoadjuvant Therapy 2Filgrastim 2oblimersen 1Trastuzumab 1Taxes 1Tamoxifen 1Radiotherapy 1Radiation 1Paclitaxel 1Methotrexate 1Leucovorin 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Epirubicin 1Docetaxel 1Cisplatin 1Chemotherapy, Adjuvant 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cardiotoxicity × oblimersen × Clear all
NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡